Sperm protein 17 is a suitable target for adoptive T-cell-based immunotherapy in human ovarian cancer

Journal of Immunotherapy

Volumn 31, Issue 8, 2008, Pages 693-703

  Chiriva Internati, Maurizio ^a,b,e   Weidanz, Jon A ^b   Yu, Yuefei ^a,b   Frezza, Eldo E ^a,c   Jenkins, Marjorie R ^c   Kennedy, Ronald C ^a   Cobos, Everardo ^a,b   Kast, W Martin ^d  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e TEXAS TECH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER TESTIS ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SP17CTL; SPERM PROTEIN 17; UNCLASSIFIED DRUG; CARRIER PROTEIN; MEMBRANE ANTIGEN; SPA17 PROTEIN, HUMAN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RELAPSE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN TARGETING; ANIMAL; IMMUNOLOGY; MALE; METABOLISM; METHODOLOGY; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; OVARY TUMOR; PATHOLOGY; TRANSPLANTATION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, SURFACE; CARRIER PROTEINS; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MALE; MICE; MICE, INBRED NOD; MICE, SCID; OVARIAN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 59849106610     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31818283d5     Document Type: Article

References (35)

1. Gattinoni L, Powell DJ Jr, Rosenberg SA, et al. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006;6:383-393.
2. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126-129.
3. Chiriva-Internati M, Grizzi F, Weidanz JA, et al. A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17. J Immunol Methods. 2007;321:86-93.
4. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
5. Jemal A, Murray T, Ward E, et al. Cancer Statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
6. Cheng W, Liu J, Yoshida H, et al. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med. 2005;1 1:531-537.
7. Feeley KM, Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology. 2001;38:87-95.
8. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915.
9. Hwu P, Freedman RS. The immunotherapy of patients with ovarian cancer. J Immunother. 2002;25:189-201.
10. Karanikas V, Lurquin C, Didier Colau D, et al. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canary pox virus. J Immunol. 2003;171:4898-4904.
11. Coulie PG, Karanikas V, Lurquin C, et al. Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. Immunol Rev. 2002;188:33-42.
12. Boon T, Coulie PG, Van Den Eynde BJ, et al. Human T cell responses against melanoma. Annu Rev Immunol. 2006;24:175-208.
13. Rosenberg SA. Progress in human tumor immunology and immunotherapy. Nature. 2001;411:380-384.
14. Scanlan MJ, Andrew JG, Old LJ. The cancer testis genes: review, standardization and commentary. Cancer Immunity. 2004;4:1-15.
15. Grizzi F, Gaetani P, Franceschini B, et al. Sperm protein 17 is expressed in human nervous system tumors. BMC Cancer. 2006;6:23-29.
16. O'Rand MG, Widgren EE, Fisher SJ. Characterization of rabbit sperm membrane autoantigen, RSA, as lectin zona binding protein. Dev Biol. 1988;129:231-240.
17. Straughn JM Jr, Shaw DR, Guerrero A, et al. Expression of sperm protein 17 (Sp-17) in ovarian cancer. Int J Cancer. 2004;108:805-811.
18. Wen Y, Richardson RT, Widgren EE, et al. Characterization of Sp17: a ubiquitous three domain protein that binds heparin. Biochem J. 2001;357:25-31.
19. Lim SH, Wang Z, Chiriva-Internati M, et al. Sperm protein 17 is a novel cancer testis antigen in multiple myeloma. Blood. 2001;97:1508-1510.
20. Chiriva-Internati M, Wang Z, Salati E, et al. Sperm protein 17 (Sp17) as a target for immunotherapy of ovarian cancer. Cancer. 2002;94:2447-2453.
21. Chiriva-Internati M, Wang Z, Xue Y, et al. Sperm protein 17 (Sp17) in multiple myeloma: opportunity for myeloma-specific donor T cell infusion to enhance graft-versus-myeloma effect without increasing graft-versus-host disease risk. Eur J Immunol. 2001;31:2277-2283.
22. Chiriva-Internati M, Wang Z, Salati E, et al. Successful generation of sperm protein 17 (Sp17)-specific cytotoxic T lymphocytes from healthy donors: implication for tumor-specific adoptive immunotherapy following allogeneic stem cell transplantation for Sp17-positive multiple myeloma. Scand J Immunol. 2002;56:429-433.
23. Chiriva-Internati M, Wang Z, Salati E, et al. Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma. Blood. 2002;100:961-965.
24. Grizzi F, Chiriva-Internati M, Franceschini B, et al. Immunolocalization of sperm protein 17 in human testis and ejaculated spermatozoa. J Histochem Cytochem. 2003;51:1245-1248.
25. Weidanz JA, Nguyen T, Woodburn T, et al. Levels of specific peptide-HLA class I complex predicts tumor cell susceptibility to CTL killing. J Immunol. 2006;177:5088-5097.
26. Chiriva-Internati M, Wang Z, Pochopien S, et al. Identification of a sperm protein 17 CTL epitope restricted by HLA-A1. Int J Cancer. 2003;107:863-865.
27. Chiriva-Internati M, Liu Y, Weidanz JA, et al. Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24. Blood. 2003;102:3100-3107.
28. Kershaw MH, Wang G, Westwood JA, et al. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther. 2002;13:1971-1980.
29. Soler D, Humphreys TL, Spinola SM, et al. CCR4 versus CCR10 in human cutaneous TH lymphocyte trafficking. Blood. 2003;101:1677-1682.
30. Ali S, Ahmad M, Lynam J, et al. Trafficking of tumor peptide-specific cytotoxic T lymphocytes into the tumor microcirculation. Int J Cancer. 2004;110:239-244.
31. Frayne J, Hall L. A re-evaluation of sperm protein 17 (Sp17) indicates a regulatory role in an A-kinase anchoring protein complex, rather than a unique role in sperm-zona pellucida binding. Reproduction. 2002;124:767-774.
32. Nakazato T, Kanuma T, Tamura T, et al. Sperm protein 17 influences the tissue-specific malignancy of clear cell adenocarcinoma in human epithelial ovarian cancer. Int J Gynecol Cancer. 2007;17:426-432.
33. Grizzi F, Chiriva-Internati M, Franceschini B, et al. Sperm protein 17 is expressed in human somatic ciliated epithelia. J Histochem Cytochem. 2004;52:549-554.
34. Overwijk WW, Lee DS, Surman DR, et al. Vaccination with a recombinant vaccinia virus encoding a "self antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4 (+) T lymphocytes. Proc Natl Acad Sci USA. 1999;96:2982-2987.
35. Dadabayev AR, Wang Z, Zhang Y, et al. Cancer immunotherapy targeting Sp17: when should the laboratory findings be translated to the clinics? Am J Hematol. 2005;80:6-11.